|
NovaHep is based on research conducted at the Huddinge unit of the Karolinska Institute in
Stockholm.
The results of stem-cell
research show a promising way of using liver cells as a base for gene
therapy of liver diseases, such as Hepatitis C.
The company will continue
to further document the therapeutic and clinical use of liver cells in areas
of great medical needs.
NovaHep’s intention is to
increase its research resources in this field and to accelerate the
development process. The objective is to offer a wide range of new
therapeutic treatments for such patients on a global basis.
|